Palatin’s stock plum­mets 43% as lead as­set fails PhI­II dry eye co-pri­ma­ry end­points

Al­though Palatin Tech­nolo­gies’ lead drug can­di­date missed a pair of pri­ma­ry end­points in a Phase III dry eye dis­ease tri­al, the com­pa­ny be­lieves there’s still a fu­ture for the as­set af­ter fur­ther analy­sis ad­just­ed for study par­tic­i­pants’ age and gen­der.

The MELODY-1 tri­al in­ves­ti­gat­ed the melanocortin re­cep­tor pan-ag­o­nist, dubbed PL9643, ad­min­is­tered three times a day for 12 weeks ver­sus ve­hi­cle oph­thalmic so­lu­tion in dry eye dis­ease (DED). Per a planned analy­sis, the can­di­date missed sig­nif­i­cance in the co-pri­ma­ry end­points of change in pain and con­junc­ti­val lis­samine green stain­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER